title: [Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases].
abstract: BACKGROUND
  Leishmaniasis is wide spread parasitic disease considered to be endemic in 88 countries in both old and new world. The standard treatment remains Meglumine antimoniate.
  
  
  OBJECTIVE
  We study the side effects of systemic meglumine antimoniate in cutaneous leishmaniasis.
  
  
  METHODS
  We conduct a retrospective study covering 3-year period (2002- 2005). All medical reports of cutaneous leishmaniasis treated by systemic Meglumine antimoniate are reviewed.
  
  
  RESULTS
  The study comprise 63 patients all treated by systemic meglumine antimoniate at the dose of 60 mg/kg/day for 10-15 days. Side effects were noted in 15 cases (12 females and 3 males). The subject's age range from 11 to 78 years. Stibio-intolerance (fever, rash, arthralgia, abdominal pain) was observed in 12 cases and stibiotoxicity in 3 cases: precordialgies 1 case, hyperamylasemia and increase liver enzyme: 1 case, pancytopenia, renal and hepatic failure leading to death: 1 case, skin eruption: 7 cases, pruritus and erythema in the site of injection: 5 cases, urticaria: 1 case. Meglumine antimoniate was stopped in 13 cases.
  
  
  CONCLUSIONS
  Meglumine antimoniate is the generally recommended treatment of cutaneous leishmaniasis. In spite of the rarity of Glucantime's side effects, we recommend a careful survey especially in older patients.
authors.affiliation: Service de Dermatologie, Hôpital Charles Nicolle, Boulevard 9 Avril, Tunis, Tunisie.
authors.forename: Nadia
authors.initials: N
authors.lastname: Ezzine Sebai
authors.forename: Nozha
authors.initials: N
authors.lastname: Mrabet
authors.forename: Aida
authors.initials: A
authors.lastname: Khaled
authors.forename: Faten
authors.initials: F
authors.lastname: Zeglaoui
authors.forename: Monia
authors.initials: M
authors.lastname: Kharfi
authors.forename: Bécima
authors.initials: B
authors.lastname: Fazaa
authors.forename: Mohamed Ridha
authors.initials: MR
authors.lastname: Kamoun
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular / Q000009:adverse effects; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000009:adverse effects*; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate